Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ABSI vs RGNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ABSI Captures Overall Composite Edge (41.2 SELL vs 45.3 HOLD), While RGNX Leads 4–2 on Growth & Valuation Pillars
ABSI Overall Winner
6-Pillar Tally: ABSI 2 – 4 RGNX
Matrix Metrics: ABSI 5 – 3 RGNX
As of Nov 16, 2026, Absci Corporation (ABSI) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (41.2/100 SELL vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. ABSI trades at $7.58 (N/M Forward P/E, -9108.3% operating margin) versus RGNX at $7.45 (N/M Forward P/E, -120.4% operating margin).
- Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. ABSI 41.2/100 SELL), ABSI captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-9108.3% vs. -120.4% operating margin) and revenue trajectory (-19.6% vs. -69.2% YoY).
- Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 38.8); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ABSI vs RGNX
ABSI
Head-to-Head Winner
Absci Corporation Common Stock
$7.58
-10.36% 1D
Market Cap
$1.6B
TTM Revenue
$1.5M
Forward P/E
N/M
Beta / 30D Vol
3.32β · 127% Vol
Unified Composite Score
41.2
SELL
Tech 30.0
Fund 51.0
Flow 71.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
RGNX
REGENXBIO Inc.
$7.45
-2.49% 1D
Market Cap
$500.9M
TTM Revenue
$154M
Forward P/E
N/M
Beta / 30D Vol
1.82β · 76% Vol
Unified Composite Score
45.3
HOLD
Tech 36.0
Fund 44.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (ABSI 2 – 4 RGNX)
1. Valuation Multiples
RGNX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
0.26x
EV / Revenue
N/M
3.1x
2. Growth & Scale
ABSI
Revenue Growth (YoY)
-19.6%
-69.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1.5M
$154M
Market Cap
$1.6B
$500.9M
3. Profitability & Quality
RGNX
Gross Margin
N/A
-64.5%
Operating Margin
-9108.3%
-120.4%
Net Profit Margin
0.0%
-113.9%
Return on Equity (ROE)
-58.6%
-113.2%
4. Balance Sheet & Cash Flow
RGNX
Cash Generation (TTM)
-$112M
-$155M
Cash Flow Margin
N/A
-100.6%
Net Cash / Leverage
$10M Net Cash
$29M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ABSI
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
169.1% (15th %ile)
349.6% (52nd %ile)
Put/Call OI Skew
0.57x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat
RGNX
OpEx & R&D Intensity
N/A
55.9% of Rev ($86M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ABSI (5) vs RGNX (3)| Institutional Metric | ABSI | RGNX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.6B | $500.9M | ABSI | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -19.6% | -69.2% | ABSI | |
| Operating Margin (TTM) | -9108.3% | -120.4% | RGNX | |
| Net Profit Margin | 0.0% | -113.9% | ABSI | |
| Return on Equity (ROE) | -58.6% | -113.2% | ABSI | |
| 52-Week Range Position | 52% ($2–$13) | 19% ($5–$16) | ABSI | |
| Beta / 30D Volatility | 3.32β · 127% Vol | 1.82β · 76% Vol | RGNX | |
| Unified Institutional Score | 41.2 / 100 (SELL) | 45.3 / 100 (HOLD) | RGNX | |
| Trailing 12M Revenue (USD) | $1.5M | $154M | Scale | |
| Gross Profit Margin (TTM) | N/A | -64.5% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 0.26x PEG · 3.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$112M ($10M Net Cash) | -$155M ($29M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
RGNX +15.76 pp
3M Horizon
ABSI +18.29 pp
6M Horizon
ABSI +21.33 pp
1Y Horizon
ABSI +222.93 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABSI Revenue | RGNX Revenue | ABSI Op. Margin | RGNX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $220M | N/A | 40.3% | RGNX |
| FY2019 | N/A | $40M | N/A | -422.9% | RGNX |
| FY2020 | $0M | $150M | -278.3% | -77.1% | RGNX |
| FY2021 | $0M | $470M | -1573.4% | 34.0% | RGNX |
| FY2022 | $10M | $110M | -1857.5% | -233.2% | RGNX |
| FY2023 | $10M | $90M | -2020.2% | -297.1% | RGNX |
| FY2024 | $0M | $80M | -2401.6% | -280.0% | RGNX |
| FY2025 | $0M | $170M | -4297.0% | -94.6% | RGNX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ABSI
BREAKDOWN
Current IV
169.1%
IV Percentile
15th %ile
Put/Call OI Skew
0.57x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RGNX
BREAKDOWN
Current IV
349.6%
IV Percentile
52nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ABSI Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
RGNX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
55.9% of Rev ($86M)
90D Engineering Disclosures
0 Published
Investor FAQ ABSI vs RGNX Key Questions & Quantitative Answers
As of Nov 16, 2026, Absci Corporation (ABSI) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (41.2/100 SELL vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. ABSI trades at $7.58 (N/M Forward P/E, -9108.3% operating margin) versus RGNX at $7.45 (N/M Forward P/E, -120.4% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. ABSI 41.2/100 SELL), ABSI captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-9108.3% vs. -120.4% operating margin) and revenue trajectory (-19.6% vs. -69.2% YoY). Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 38.8); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABSI leads the Growth & Scale pillar: ABSI posts -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ABSI cumulative revenue shifted +0.0% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, ABSI deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.
RGNX screens cheaper on headline valuation multiples. ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABSI (-58.6% ROE) versus RGNX (-113.2% ROE) capital efficiency.
In options market volatility and institutional positioning, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.32β · 127% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RGNX vs ABSI · Reverse Pair
ABSI vs PRME
· Sector Peer
ABSI vs RLAY
· Sector Peer
ABSI vs ABCL
· Sector Peer
RGNX vs QURE
· Sector Peer
RGNX vs MGTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem